ClinicalTrials.gg
Not yet recruitingNCT06763302Updated Jan 8, 2025

NGS MRD-Guided Blinatumomab Treatment for Pediatric B-ALL

An interventional study of Blinatumomab in B Cell Precursor Acute Lymphoblastic Leukemia, Pediatric and Minimal Residual Disease, sponsored by The Children's Hospital of Zhejiang University School of Medicine. Not yet recruiting. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2025-01-08.

Sponsored by The Children's Hospital of Zhejiang University School of Medicine · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,220
Allocation
Randomized
Ages
1 Year to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies testing blinatumomab in Neoplasm, Residual — 3 open to participants now, 6 under way, none of them phase 3. blinatumomab · Neoplasm, Residual.

Planned enrollment
Largest of 17
1,220 · median 31
Started
2025
with 2 others
No phase
2 of 17
2 open now
Registered
15th of 17
by date
Lead sponsor
1 of 17
The Children's Hospital of Zhejiang University School of Medicine

Among the 17 studies testing blinatumomab in Neoplasm, Residual, this one has the largest planned enrollment, is one of 3 that started in 2025, is one of 2 with no phase, and was the 15th registered.

Neoplasm, Residual

294 studies on the registry are indexed under Neoplasm, Residual; 137 are open to participants now.

Browse Neoplasm, Residual studies →

Open to participants now

3 of the 17 studies testing blinatumomab in Neoplasm, Residual are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About blinatumomab

blinatumomab: first FDA approval 2014 (BLINCYTO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 93 Neoplasm, Residual studies recruiting now, 59 (63%) set no upper age limit and 24 (26%) stop at 75 or younger; 18 take children under 18; 7 take healthy volunteers.

This study: 1 Year to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing blinatumomab in Neoplasm, Residual, or all of them as a file.
02

Study summary

The goal of this clinical trial is to determine whether pediatric B-cell acute lymphoblastic leukemia (B-ALL) patients with negative deep minimal residue disease (MRD) can benefit from blinatumomab treatment.

The main questions it aims to answer are:

  1. Whether the application of blinatumomab can improve the long-term survival of next generation sequence (NGS) MRD-positive B-ALL children after consolidation therapy?
  2. Whether the application of blinatumomab can benefit the NGS MRD-negative B-ALL children after consolidation therapy?
03

Conditions studied

  • B Cell Precursor Acute Lymphoblastic Leukemia
  • Pediatric
  • Minimal Residual Disease
  • Next Generation Sequencing (NGS)

Browse trials for

04

Who can participate

Ages eligible
1 Year to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clincial dianogsis of acute lymphoblastic leukemia (B-cell type) by morphology, immunology, cytogenetics, and molecular biology (MICM).
  • Age ≥1 year and \<18 years.
  • signed, with the parents or guardians agreeing to a unified treatment protocol.

Exclusion criteria

Exclusion Criteria:

  • Age \<1 year or ≥18 years.
  • Immunophenotyping suggests mature B-cell leukemia, mixed-lineage leukemia, or T-cell acute lymphoblastic leukemia.
  • Secondary leukemia or second tumor, CML blast phase ALL.
  • Other tumors or immunodeficiency diseases present.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,220 participants (estimated)

Study arms

  • Experimental
    EOC NGS MRD positive Group

    Based on the B-ALL treatment protocol, NGS MRD levels will be monitored at the end of consolidation treatment (EOC). If NGS MRD is positive (≥0.0001%), one course of blinatumomab (28 days) will be added after the consolidation treatment.

    Drug: Blinatumomab

  • Active comparator
    EOC NGS MRD negative Group A

    Based on the B-ALL treatment protocol, NGS MRD levels will be monitored at the end of consolidation treatment (EOC). If NGS MRD is negative (\< 0.0001%), the IR/HR patients will be randomized into A and B two groups. EOC NGS MRD negative Group A will be added by one course of blinatumomab (28 days) treatment after the consolidation treatment.

    Drug: Blinatumomab

  • No intervention
    EOC NGS MRD negative Group B

    Based on the B-ALL treatment protocol, NGS MRD levels will be monitored at the end of consolidation treatment (EOC). If NGS MRD is negative (\< 0.0001%), the IR/HR patients will be randomized into A and B two groups. EOC NGS MRD negative Group B will continue the original chemotherapy treatment plan.

Interventions

  • The FDA has approved blinatumomab for post-consolidation treatment in all Ph-negative B-ALL cases, regardless of MRD status. Considering the high cost of blinatumomab and the financial burden on families, we aim to precisely identify the population who would benefit from blinatumomab and provide appropriate treatment.

06

What researchers measure

Primary outcomes

  1. event free survival

    Death during induction, abandonment before complete remission, death in continuous complete remission, relapse, and secondary Death during induction, abandonment before complete remission (CR), death in continuous complete remission (CCR), relapse, and secondary malignancies were considered as events in the calculation of EFS probability.

    Time frame: From enrollment to the 3-year after the end of treatment

  2. Relapse free survival

    RFS was measured by the time from achievement of CR to last follow-up or first relapse and censored at the first event (death, secondary malignancies) except relapse.

    Time frame: From enrollment to the 3-year after the end of treatment

Secondary outcomes

  1. Treatment-Related Adverse Events as Assessed by CTCAE v4.0

    Time frame: From enrollment to the 3-year after the end of treatment

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Chen H, Gu M, Liang J, Song H, Zhang J, Xu W, Zhao F, Shen D, Shen H, Liao C, Tang Y, Xu X. Minimal residual disease detection by next-generation sequencing of different immunoglobulin gene rearrangements in pediatric B-ALL. Nat Commun. 2023 Nov 17;14(1):7468. doi: 10.1038/s41467-023-43171-9. PubMed 37978187 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2025; primary completion for Dec 2027, 35 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2024
First posted
Jan 8, 2025
StartEst.
Jan 1, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2030
Last update
Jan 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06763302
Lead sponsor
The Children's Hospital of Zhejiang University School of Medicine
Responsible party
Xiaojun Xu (Professor, The Children's Hospital of Zhejiang University School of Medicine) — Principal investigator
First posted
Jan 8, 2025
Start date
Jan 1, 2025 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Jan 8, 2025

Study contacts

Xiaojun Xu
Contact
xuxiaojun@zju.edu.cn
+86-571-88873450

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Blinatumomab

Start the discussion